Impact of Brokerage Rating on Masimo Corporation(MASI)

Many Masimo Corporation(MASI) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Masimo Corporation was Downgraded by Raymond James to Mkt Perform on Feb 13, 2017.

Company has reported several Insider transactions to the SEC, on Feb 7, 2017, Raad Mark De (EVP & Chief Financial Officer) sold 15,000 shares at 75.00 per share price.On Feb 7, 2017, Jon Coleman (Pres-WW Sales,Pro Svc,Med Affs) sold 6,000 shares at 75.00 per share price.On Feb 3, 2017, Yongsam Lee (EVP & CIO) sold 10,000 shares at 74.00 per share price.

Masimo Corporation Last issued its quarterly earnings results on Feb 14, 2017. The company reported $0.46 EPS for the quarter, missing the analyst consensus estimate by $ -0.06. Analyst had a consensus of $0.52. The company had revenue of $183.20 million for the quarter, compared to analysts expectations of $180.48 million. The companys revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.15 EPS.

Masimo Corporation (NASDAQ:MASI) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 2 by 6 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold.

Masimo Corporation (NASDAQ:MASI): The mean estimate for the short term price target for Masimo Corporation (NASDAQ:MASI) stands at $63.5 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $75 while the lower price target estimate is at $55.

Masimo Corporation (NASDAQ:MASI) rose 1.72% or 1.3 points on Tuesday and made its way into the gainers of the day. After trading began at $75.39 the stock was seen hitting $77.169 as a peak level and $75.06 as the lowest level. The stock ended up at $76.99. The daily volume was measured at 759,055 shares. The 52-week high of the share price is $77.18 and the 52-week low is $33.03. The company has a market cap of $3,825 million.

Masimo develops innovative monitoring technologies that significantly improve patient care — helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced alarms and increased pulse oximetrys ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.


Share this post

Leave a Reply